Enhua Pharmaceutical (002262.SZ) released its financial performance for the first half of the year, with a net profit attributable to the parent company of 700 million yuan, an increase of 11.38%.

China Fortune Financial News App reported that Enhua Pharmaceutical (002262.SZ) released its 2025 interim report. The company's operating income was 3.01 billion yuan, an increase of 8.93% year-on-year. Net profit attributable to shareholders of the listed company was 700 million yuan, an increase of 11.38% year-on-year. Net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 699 million yuan, an increase of 10.33% year-on-year. Basic earnings per share were 0.69 yuan.